Spike Protein & modRNA Detected in Vaccinated Blood Well After A Few Days (Part 3)
In a recent review of the current evidence for modRNA biodistribution beyond the injection site, four Russian authors, publishing in the peer-reviewed open access Biomedicines, forwarded the most probable explanation for why the official narrative about quick modRNA clearance from the blood differs so drastically from the emerging evidence of prolonged modRNA detection in blood samples for more than 2 weeks after the last dose; Pfizer and Moderna performed their preclinical pharmacokinetic experiments on rodents only. Moderna’s preclinical study established a modRNA plasma half-life of 2.7-3.8 hours with no detectable levels after a day - in rodents. However as the authors note this observation isn’t directly transferable to humans:
Experiments on rodents typically involve a smaller number of samples taken at different time points and smaller plasma sample volumes as compared to larger species such as humans, even though the doses of mRNA vaccines for rodents and humans are similar. Consequently, larger species are likely to exhibit significantly longer t1/2 due to the higher analytical sensitivity.
They also point out that bio-distribution studies Pfizer and Moderna conducted on rodents were limited to reporter proteins and did not assess the distribution of encoded antigens such as the spike protein fragment S1. When the spike and S1 antigen were measured separately in a human study, published in Clinical Infectious Diseases, concentrations of the latter peaked on day 5 and became undetectable on day 14 while the spike was nearly undetectable on day 7 but peaked on day 15. The explanation put forward for this is that the immune cells eliminate the antigen presenting cells freeing cleaved S1 and full length spike to continue circulating in the plasma.
A recent breakthrough study that assessed blood samples taken from long COVID patients (n = 81) via mass spectrometry found fragments of the vaccine spike protein, which differs from the viral protein by a double proline amino acid substitution and use of 1-methyl pseudouridine in place of uridine, in 2 samples, fragments of the viral spike protein in one sample and no fragments in any of the control group samples. The 2 samples that were contaminated with fragments of the vaccine spike protein were collected 2 months after the patients were administered their second Pfizer shot.
Another mass spectrometry study of blood samples taken from patients suffering from long Vaxx symptoms (n = 50), and compared to a similar number of controls (n =45), found that the former still had S1 and S2 fragments in their monocyte white blood cells months after their last dose with an average of 105 days from their last dose to sample collection with a minimum of 38 days and a maximum of 245 days (over 8 months later). Symptoms ranged from fatigue (28/50), neuropathy (27/50), brain fog (23/50) and headache (23/50).
As Preez and colleagues point out in their literature review article on the Pathophysiology of Undersulfated and Degraded Glycocalyx the distribution and absorption of LNPs throughout the body is contingent on their ‘administration routes, physicochemical properties, particle agglomeration, and surface coatings’ and note that particles this small can circulate in the lymph system and blood and be retained in various organs. They can also cross the blood brain barrier and blood placental barrier. The authors also note the particular polyethylene glycol (PEG) coated LNP used by both Pfizer and Moderna are ionizable and PH sensitive and therefore have a positive charge under low PH conditions which affects their bio-distribution and clearance from the body.